Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 19;13:7120. doi: 10.1038/s41467-022-34400-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, b Comparison of plasma neutralizing activities in different groups against WT SARS-CoV-2 and Omicron subvariants at Visit 1 (early stage of infection) (a) and Visit 2 (convalescent period) (b). c, d Neutralization titers against WT SARS-CoV-2 and Omicron subvariants in BA.2 breakthrough infected individuals with 2-dose (c) and 3-dose (d) inactivated vaccines. e, f Enhancement effects of neutralization against WT SARS-CoV-2 and Omicron subvariants by BA.2 breakthrough infection in 2-dose (e) and 3-dose (f) group. g Fold change in the enhanced neutralization of WT SARS-CoV-2 and Omicron subvariants by BA.2 breakthrough infection. h Correlation analysis between ID₅₀ values against WT SARS-CoV-2 at Visit 1 and fold changes of enhanced neutralization in the 34 BA.2 breakthrough infected individuals. Perfect-fit correlation line was included on the plot. The non-parametric Spearman’s correlation coefficients (R) and statistically significant P value were provided. The ID₅₀ values are means of at least two independent experiments. Data are presented as geometric mean values ± standard deviation (SD). The sample size, geometric mean, fold change, and significance of difference were labelled on the top. “-” represents decreased value and “+” represents increased value. Statistical significance was performed using two-tailed unpaired Wilcoxon test in (a, b), two-tailed Kruskal-Wallis test with paired Wilcoxon’s multiple-comparison test in (c, d, g), and two-tailed paired Wilcoxon test in (e, f). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, not significant. The dotted horizontal line in (a-f) indicates the limit of detection (1:20 dilution) for the neutralization assay. Non-neutralization data is set as 20 for analysis and visualization. ID₅₀ indicates 50% inhibition dilution. GMT indicates geometric mean titer. FC indicates fold change. Source data and exact P values are provided as a Source Data file.